Pharma BD Deal Intelligence
Pfizer and BioNTech entered a collaboration to develop mRNA-based influenza vaccines using BioNTech's proprietary mRNA platform technology. Pfizer paid $120M upfront and BioNTech is eligible for up to $305M in development and commercial milestones. This deal established the Pfizer-BioNTech partnership that later became the foundation for the COVID-19 vaccine collaboration (BNT162b2/Comirnaty).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / BioNTech SE (this deal) | 2018 | $425M | 59 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2018 deals · Pfizer Inc. deals · Infectious Disease deals